Cost calculation model of introducing Upadacitinib and Risankizumab for adult ulcerative colitis and Crohn’s disease in the Kingdom of Saudi Arabia

Mahmoud H. Mosli; Abdulelah A. Almutairdi; Abdullah M. Alshahrani; Abdulrahman M. Alkhurmi; Ahmad N. Fasseeh; Ali M. Anwar; Bandar M. Alharbi; Esraa S. Altawil; Haneen J. Alshareef; Hussain A. Alqasim; Ibtisam H. Alharbi; Kareem A. El-Fass; Layla N. Alanizy; Rayd A. Almehizia; Rok Hren; Wael K. Iskandarani; Hana A. Alabdulkarim

doi:10.4103/sjg.sjg_245_25

Citations

392

Views

Abstract not available for this publication.

Cite this Article (APA)

Mahmoud, H. M., Abdulelah, A. A., Abdullah, M. A., Abdulrahman, M. A., Ahmad, N. F., Ali, M. A., Bandar, M. A., Esraa, S. A., Haneen, J. A., Hussain, A. A., Ibtisam, H. A., Kareem, A. E., Layla, N. A., Rayd, A. A., Rok, H., Wael, K. I., Hana, A. A. (2025). Cost calculation model of introducing Upadacitinib and Risankizumab for adult ulcerative colitis and Crohn’s disease in the Kingdom of Saudi Arabia. Saudi Journal of Gastroenterology. https://doi.org/10.4103/sjg.sjg_245_25